Navigation Links
Favrille to Present at BIO InvestorForum
Date:10/2/2007

Live Webcast from the Palace Hotel in San Francisco on Wednesday, October

10th

SAN DIEGO, Oct. 2 /PRNewswire-FirstCall/ -- Favrille, Inc. (Nasdaq: FVRL), a biopharmaceutical company developing patient-specific, active immunotherapies for the treatment of cancer, today announced that Tamara Seymour, Chief Financial Officer, will present at the Biotechnology Industry Organization (BIO) InvestorForum at 10:15 a.m. Pacific time on Wednesday, October 10, 2007. The conference will be held at the Palace Hotel in San Francisco.

(Logo: http://www.newscom.com/cgi-bin/prnh/20031013/LAM095LOGO)

Ms. Seymour will provide an overview of Favrille and the clinical trials of its lead compound, FavId(R), which is currently in a pivotal Phase 3 clinical trial for the treatment of follicular B-cell non-Hodgkin's lymphoma (NHL). A live webcast of the presentation can be accessed at http://www.favrille.com. The replay will be available approximately one hour after the presentation and will be archived until November 10, 2007.

About Favrille, Inc.

Favrille, Inc. is a biopharmaceutical company focused on the development and commercialization of targeted immunotherapies for the treatment of cancer and other diseases of the immune system. The Company's lead product candidate, FavId, is based upon unique genetic information extracted from a patient's tumor. FavId is currently under investigation in a pivotal Phase 3 clinical trial for patients with follicular B-cell NHL and Phase 2 clinical trials in other B-cell NHL indications. The Company is developing additional applications based on its immunotherapy expertise and proprietary cost-effective manufacturing technology, including a second product candidate, FAV-201, for the treatment of cutaneous T-cell lymphoma.


'/>"/>
SOURCE Favrille, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1

Related biology technology :

1. Amplification of genome-representative DNA from limited sources with GenomePlex WGA technology for use in genetic alterations studies
2. Wisconsin firms to present at Cleantech venture capital event
3. New Sonic Foundry search engine finds words, phrases in video presentations
4. Lone Wisconsin firm to present at InvestMidwest
5. Sonic Foundry creates search engine for 7,000 expert video presentations
6. InvestMidWest calls for business presentations
7. Wicab to present BrainPort at Boston conference
8. Three more Wisconsin firms to present at venture forum
9. Six Wisconsin firms to present at BIO Mid-America VentureForum
10. New Health and Human Services representative for Midwest
11. Top 20 big pharmas represent majority of world pharma market
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/15/2017)... , ... May 15, 2017 , ... ... and development solutions for drugs, biologics and consumer health products, today announced that ... on rare genetic diseases, to support preclinical and clinical development of TA-46, a ...
(Date:5/15/2017)... 15, 2017  IBM (NYSE: IBM ) scientists ... double-stranded DNA molecules with the potential to efficiently ... This technology complements the IBM Research,s "lab-on-a-chip" ... exosomes and which may also contain biomarkers for ... array of diamond shaped micropillars 1 to ...
(Date:5/11/2017)... May 11, 2017   BioLife Solutions , Inc. (NASDAQ: ... of proprietary clinical grade cell and tissue hypothermic storage ... "Company"), today reported operational highlights and financial results for the ... product sales reached a new high of $2.4 million in ... the same period in 2016. Revenue growth was driven by ...
(Date:5/11/2017)... ... May 11, 2017 , ... The key to unlocking the cause ... Sclerosis (MS) is a neurological disorder that can rob people of their ability to ... own brain cells. MS arises from a genetic tendency towards the disease combined with ...
Breaking Biology Technology:
(Date:4/5/2017)... KEY FINDINGS The global market ... CAGR of 25.76% during the forecast period of 2017-2025. ... for the growth of the stem cell market. ... MARKET INSIGHTS The global stem cell market is segmented ... The stem cell market of the product is segmented ...
(Date:3/30/2017)... The research team of The Hong Kong Polytechnic University (PolyU) ... ground breaking 3D fingerprint minutiae recovery and matching technology, pushing contactless ... use in identification, crime investigation, immigration control, security of access and ... ... A research team led by Dr Ajay Kumar ...
(Date:3/27/2017)... , March 27, 2017  Catholic Health Services ... Management Systems Society (HIMSS) Analytics for achieving Stage ... Model sm . In addition, CHS previously earned ... hospitals using an electronic medical record (EMR). ... high level of EMR usage in an outpatient ...
Breaking Biology News(10 mins):